Hannachi Nadji, Camoin-Jau Laurence
Aix Marseille Univ, IRD, APHM, MEPHI, IHU Méditerranée Infection, 19-21 Boulevard Jean Moulin, 13005 Marseille, France.
Département de Pharmacie, Faculté de Médecine, Université Ferhat Abbas Sétif I, Sétif 19000, Algeria.
J Pers Med. 2021 Apr 25;11(5):345. doi: 10.3390/jpm11050345.
Interindividual heterogeneity in response to treatment is a real public health problem. It is a factor that can be responsible not only for ineffectiveness or fatal toxicity but also for hospitalization due to iatrogenic effects, thus increasing the cost of patient care. Several research teams have been interested in what may be at the origin of these phenomena, particularly at the genetic level and the basal activity of organs dedicated to the inactivation and elimination of drug molecules. Today, a new branch is being set up, explaining the enigmatic part that could not be explained before. Pharmacomicrobiomics attempts to investigate the interactions between bacteria, especially those in the gut, and drug response. In this review, we provide a state of the art on what this field has brought as new information and discuss the challenges that lie ahead to see the real application in clinical practice.
治疗反应的个体间异质性是一个切实存在的公共卫生问题。这一因素不仅可能导致治疗无效或致命毒性，还可能因医源性效应导致患者住院，从而增加患者护理成本。几个研究团队对这些现象的起源感兴趣，特别是在基因层面以及负责药物分子失活和消除的器官的基础活性方面。如今，一个新的分支正在建立，解释之前无法解释的神秘部分。药物微生物组学试图研究细菌之间的相互作用，尤其是肠道中的细菌与药物反应之间的相互作用。在这篇综述中，我们介绍了该领域带来的新信息，并讨论了在临床实践中实现实际应用面临的挑战。
